ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
三倍做多標普生物-Direxion
250.40
-17.9900
-6.70%
盤前:
252.05
1.65
+0.66%
05:40 EDT
成交量:
32.56萬
成交額:
8,161.00萬
市值:
4.94億
市盈率:
- -
高:
267.90
開:
266.14
低:
243.24
收:
268.39
52周最高:
341.93
52周最低:
76.29
股本:
197.45萬
流通股本:
197.45萬
量比:
1.30
換手率:
16.49%
股息:
1.00
股息率:
0.40%
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
梯瓦製藥的妥瑞氏綜合徵療法獲美國FDA優先審評
格隆汇
·
08/19
梯瓦製藥的Ecopipam新藥申請獲得美國食品藥品監督管理局(FDA)優先審評資格。
智通财经
·
08/19
曾輝:銀河通用在文旅消費、工業製造、醫療健康等領域實現規模商用
睿见Economy
·
08/19
醫療板塊市場快訊匯總:多家機構研判行業動向
投资观察
·
08/19
全民醫療保障「十五五」規劃:大力推動商業醫療保險發展
智通财经
·
08/19
全民醫療保障「十五五」規劃:大力推動商業醫療保險發展
智通财经
·
08/19
國家醫保局:大力推動商業醫療保險發展
金吾财讯
·
08/19
《全民醫療保障「十五五」規劃》發布
金吾财讯
·
08/19
國家醫保局:大力推動商業醫療保險發展
格隆汇
·
08/19
國家醫保局:提高基金抗風險能力和使用效率,到2029年基本實現省級統籌
格隆汇
·
08/19
《全民醫療保障「十五五」規劃》發布
格隆汇
·
08/19
市場消息:特朗普將任命白宮顧問海蒂·奧弗頓擔任FDA局長。
格隆汇
·
08/19
醫療健康板塊市場動態綜述
投资观察
·
08/19
據福克斯新聞:美國眾議員巴迪·卡特已與白宮討論其出任下一任美國食品藥品監督管理局(FDA)局長的可能性。消息人士稱,卡特
格隆汇
·
08/19
醫療保健板塊市場快訊匯總
投资观察
·
08/19
美國FDA就生成式AI醫療設備相關法規徵集公眾意見。
智通财经
·
08/18
醫療健康板塊市場快訊綜述
投资观察
·
08/18
北汽副總史志山年薪75.41萬元 連續兩年低於同期上任的副總胡漢軍
运营商财经网
·
08/18
傳童牧知擬加盟瑞銀 出任集團亞洲醫療保健投行業務主席
智通财经
·
08/18
醫療保健板塊動態:市場快訊匯總
投资观察
·
08/18
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/LABU/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":250.4,"timestamp":1789502400000,"preClose":268.39,"halted":0,"volume":325606,"hourTrading":{"tag":"盘前","latestPrice":252.05,"preClose":250.4,"latestTime":"05:40 EDT","volume":1660,"amount":419145.4184,"timestamp":1789551603457,"change":1.65,"changeRate":0.006589,"amplitude":0.007588},"delay":0,"changeRate":-0.0670293230001117,"floatShares":1974486,"shares":1974486,"eps":0,"marketStatus":"盤前交易","change":-17.99,"latestTime":"09-16 05:56:03 EDT","open":266.14,"high":267.9,"low":243.2444,"amount":81609965.98544,"amplitude":0.091865,"askPrice":252.63,"askSize":2,"bidPrice":251.81,"bidSize":2,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789565400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":250.4,"sharesOutstanding":3074486,"nav":268.659,"aum":530464172.89,"dividendRate":0.004,"bidAskSpread":0.003539,"preHourTrading":{"tag":"盘前","latestPrice":252.05,"preClose":250.4,"latestTime":"05:40 EDT","volume":1660,"amount":419145.4184,"timestamp":1789551603457,"change":1.65,"changeRate":0.006589,"amplitude":0.007588},"postHourTrading":{"tag":"盘后","latestPrice":251.98,"preClose":250.4,"latestTime":"19:59 EDT","volume":8108,"amount":2036460.6035,"timestamp":1789516773600,"change":1.58,"changeRate":0.00631,"amplitude":0.00631},"volumeRatio":1.2973187913517363,"impliedVol":0.9273,"impliedVolPercentile":0.568},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1974486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.2973187913517363,"shares":1974486,"dividePrice":1.0016,"high":267.9,"amplitude":0.091865,"preClose":268.39,"low":243.2444,"week52Low":76.29,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":250.4,"eps":0,"divideRate":0.004,"volume":325606,"delay":0,"ttmEps":0,"open":266.14,"prevYearClose":159.39,"prevWeekClose":261.3,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":293.07,"twentyDayClose":287.3,"sixtyDayClose":206.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660421155","title":"梯瓦製藥的妥瑞氏綜合徵療法獲美國FDA優先審評","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421155","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421155?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 23:01","pubTimestamp":1787151678,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","LU1983299246.USD","BK4007","BK4596","TEVA","BK4585","BK4566","LABU","BK4559","BK4557","BK4584","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660423334","title":"梯瓦製藥的Ecopipam新藥申請獲得美國食品藥品監督管理局(FDA)優先審評資格。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660423334","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660423334?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 20:31","pubTimestamp":1787142670,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2324357040.USD","BK4557","BK4596","BK4559","BK4584","LABU","TEVA","BK4588","BK4566","BK4585","LU1983299246.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660449520","title":"曾輝:銀河通用在文旅消費、工業製造、醫療健康等領域實現規模商用","url":"https://stock-news.laohu8.com/highlight/detail?id=2660449520","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660449520?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 17:19","pubTimestamp":1787131140,"startTime":"0","endTime":"0","summary":"银河通用机器人高级副总裁曾辉出席“AI大模型赋能机器人与具身智能产业新范式交流活动”围绕打造人形机器人智能经济新生态展开分享。曾辉表示,银河通用积极响应国家关于打造智能经济新形态和实景实训的号召,在文旅消费、工业制造、医疗健康等领域实现规模商用。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-08-19/doc-ininvwqs2631907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","BK4550","IJK","BK4585","VOE","BK4581","VHT","XLV","LABU","REGL","159760","IXJ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175089982","title":"醫療板塊市場快訊匯總:多家機構研判行業動向","url":"https://stock-news.laohu8.com/highlight/detail?id=1175089982","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175089982?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:26","pubTimestamp":1787127985,"startTime":"0","endTime":"0","summary":"0722 GMT——华侨银行集团研究分析师Troy Cheng在最新报告中指出,Foundation Healthcare已占据有利位置,有望把握从住院治疗向低成本门诊治疗转型的市场机遇。Foundation Healthcare旗下拥有四家医疗中心,不仅能够获取设施和诊断相关收入,还能更好地掌控患者的康复进程。作为新加坡规模最大、增长最快的多专科医疗平台之一,该公司获得华侨银行首次覆盖,给予买入评级,合理估值定价为1.13新加坡元。该股当前报0.755新加坡元,跌幅1.3%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4585","BK4588","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448216","title":"全民醫療保障「十五五」規劃:大力推動商業醫療保險發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660448216?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 15:33","pubTimestamp":1787124830,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","XLV","BK4588","BK4585","XBI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660044829","title":"全民醫療保障「十五五」規劃:大力推動商業醫療保險發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2660044829","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660044829?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 15:33","pubTimestamp":1787124830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,8月19日,国家医疗保障局发布关于印发《全民医疗保障“十五五”规划》的通知。其中提出,大力推动商业医疗保险发展。积极支持商业医疗保险在多层次医疗保障体系中更好发挥作用,提升服务保障水平。鼓励商保与基本医保衔接互补、差异化发展。聚焦群众多样化需求,支持商保丰富产品供给。在风险可控、经营可持续基础上,积极将医疗新技术、新服务、新药品、新器械应用纳入商保保障。依法依规推进基本医保与商保数据共享、同步结算,支持商保快赔直赔。原文如下:国家医疗保障局关于印发《全民医疗保障“十五五”规划》的通知本文编选自国家医疗保障局,智通财经编辑:陈雯芳。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LABU","XBI","BK4581","XLV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660383414","title":"國家醫保局:大力推動商業醫療保險發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2660383414","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660383414?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 12:41","pubTimestamp":1787114516,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国家医保局解读《全民医疗保障“十五五”规划》。其中提出,大力推动商业医疗保险发展。积极支持引导商业医疗保险与基本医保衔接互补、差异化发展,聚焦群众多样化需求,支持商保公司丰富产品供给,重点支持发展以基本医保目录外责任为主、普惠程度高、支持医药创新发展等的商保产品,着力满足群众在基本医保之外的未被满足的保障需求,促进商业医疗保险在多层次医疗保障体系中更好发挥补充保障作用。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988704","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4588","LABU","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660411091","title":"《全民醫療保障「十五五」規劃》發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2660411091","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660411091?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 12:23","pubTimestamp":1787113383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据央视,国家医保局今天(19日)发布《全民医疗保障“十五五”规划》。“十五五”期间基本医疗保险参保率每年保持在95%左右;长期护理保险制度覆盖所有统筹地区;基本医疗保险目录内住院费用基金支付比例职工基本医疗保险稳定在80%左右,城乡居民基本医疗保险稳定在70%左右;即时结算基本医疗保险基金支出覆盖率从2025年的70%左右提高到80%以上;所有统筹地区将实现生育津贴直接发放到个人。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/Y2Y0ZjIxMzUyMzg0MDEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2Y0ZjIxMzUyMzg0MDEwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988693","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4588","LABU","BK4585","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660411172","title":"國家醫保局:大力推動商業醫療保險發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2660411172","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660411172?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 12:08","pubTimestamp":1787112519,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","BK4585","XBI","XLV","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660411173","title":"國家醫保局:提高基金抗風險能力和使用效率,到2029年基本實現省級統籌","url":"https://stock-news.laohu8.com/highlight/detail?id=2660411173","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660411173?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 12:08","pubTimestamp":1787112495,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","XBI","BK4585","LABU","BK4581","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660411656","title":"《全民醫療保障「十五五」規劃》發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2660411656","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660411656?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 11:54","pubTimestamp":1787111679,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LABU","BK4585","BK4588","XBI","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660541890","title":"市場消息:特朗普將任命白宮顧問海蒂·奧弗頓擔任FDA局長。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660541890","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660541890?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 08:03","pubTimestamp":1787097802,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199762583","title":"醫療健康板塊市場動態綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1199762583","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199762583?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 04:53","pubTimestamp":1787086408,"startTime":"0","endTime":"0","summary":"聚焦医疗健康领域的最新市场快讯。这些内容仅在道琼斯通讯社于美东时间4:20、12:20及16:50独家发布。1931 GMT——澳大利亚制药企业CSL今日股价表现值得期待,RBC资本市场如是说。CSL的2026财年基础盈利和营收均超出市场预期。CSL预计2027财年营收将与2026财年持平,同时预期在剔除汇率波动影响后基础盈利将增长5%。这意味着基础净利润将达到29.3亿美元,高于市场普遍预期的28.3亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4585","XLV","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660499297","title":"據福克斯新聞:美國眾議員巴迪·卡特已與白宮討論其出任下一任美國食品藥品監督管理局(FDA)局長的可能性。消息人士稱,卡特","url":"https://stock-news.laohu8.com/highlight/detail?id=2660499297","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660499297?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 01:54","pubTimestamp":1787075645,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["CRI","159151","BK4585","LABU","BK4202","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120479003","title":"醫療保健板塊市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1120479003","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120479003?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 00:23","pubTimestamp":1787070226,"startTime":"0","endTime":"0","summary":"医疗保健领域最新市场动态纷至沓来。这些快讯于美东时间4:20、12:20及16:50在道琼斯通讯社独家发布,为投资者带来行业前沿脉动。1931 ET——加拿大皇家银行资本市场认为,澳大利亚制药企业CSL的股价今日有望跑赢大盘。CSL预计2027财年营收将与2026财年持平,同时预期剔除汇率波动因素后基础盈利增长5%。这意味着基础净利润将达到29.3亿美元,高于市场共识预期的28.3亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588","XBI","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498276","title":"美國FDA就生成式AI醫療設備相關法規徵集公眾意見。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498276","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660498276?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 22:13","pubTimestamp":1787062401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ARTY","BK4588","QTOC","AGIX","BK4585","AIPO","VTHR","CHAT","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161501594","title":"醫療健康板塊市場快訊綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1161501594","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161501594?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 16:25","pubTimestamp":1787041508,"startTime":"0","endTime":"0","summary":"野村还将这家印度制药公司的2027和2028财年销售额预估每年上调约2.5%。分析师表示,Ipca Laboratories的印度制剂销售预计将维持低双位数的增长百分比。该券商将股票目标价从1,725.00卢比上调至2,060.00卢比,维持买入评级不变。股价目前报1,881.05卢比,下跌0.1%。1020 GMT——摩根大通分析师表示,阿斯利康终止一项肺癌药物试验令人失望,但其他药物的积极数据可能推动市场共识销售指引上调。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","XLV","LABU","BK4581","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660468932","title":"北汽副總史志山年薪75.41萬元 連續兩年低於同期上任的副總胡漢軍","url":"https://stock-news.laohu8.com/highlight/detail?id=2660468932","media":"运营商财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660468932?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 16:08","pubTimestamp":1787040480,"startTime":"0","endTime":"0","summary":"运营商财经网 汽车频道王鑫垚/文近日,北汽集团公开高管2024年薪酬情况。数据显示,胡汉军在2024年拿到薪酬77.2万元,此外还有19.67万元的社会保险、企业年金、补充医疗保险及住房公积金的单位缴存部分。两方面合计达到96.87万元;史志山2024年薪酬为75.41万元,比胡汉军低了1.79万元。据了解,胡汉军和史志山都是在2023年上任北汽集团副总经理一职。当年,史志山的税前薪酬和综合隐性福利都不如胡汉军。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-18/doc-inintpin8658136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4588","XBI","BK4581","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660683452","title":"傳童牧知擬加盟瑞銀 出任集團亞洲醫療保健投行業務主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2660683452","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660683452?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 14:08","pubTimestamp":1787033333,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,据媒体引述知情人士透露,已从高盛离职的资深投行家童牧知(Samuel Thong),拟于10月加入瑞银集团、出任瑞银亚洲医疗保健投资银行业务主席一职。资料显示,童牧知博士在医疗保健投资银行领域深耕多年,是一位资深的医疗保健投行家,从业时间约30年,拥有芝加哥大学医学博士、MBA学位。2019年,他从摩根士丹利跳槽至高盛,出任高盛投资银行部亚洲(除日本)医疗保健团队主席,并兼任该团队联席主管。于今年早些时候,他从高盛离职。在加入摩根士丹利负责亚洲医疗保健投行业务之前,他曾任职于美银美林。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IEFN","JHMF","VHT","BK4585","BK4581","BCFN","BNKO","BNKZ","KNAB","FAS","BK4582","LABU","XBI","BK4588","IAI","XLFI","BK4550","NOBL","XLV","CGVV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176123870","title":"醫療保健板塊動態:市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1176123870","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176123870?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 04:54","pubTimestamp":1787000078,"startTime":"0","endTime":"0","summary":"涵盖医疗保健领域的最新市场快讯,于美国东部时间4:20、12:20及16:50在道琼斯通讯社独家发布。根据协议,两家公司将携手推进多达十种生物类似药的开发与商业化,商业化相关付款总额最高可达3.22亿美元。塞夫顿表示,此项协议\"彰显了山德士在生物类似药商业化合作领域的领先地位\"。该药物占阿斯利康为其设定的超过50亿美元销售目标的约20%。该公司股价下跌1.2%,报0.83新加坡元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XBI","BK4585","BK4581","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}